Hepatocellular carcinoma survival with viral hepatitis and fatty liver
Part of Cancer, Digestive system clinical trials.
This study looks at how well people with liver cancer (hepatocellular carcinoma, or HCC) do when they also have viral hepatitis (hepatitis B or C) and a fatty liver condition called MASLD. It aims to understand if having both conditions affects survival outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer (HCC) using scans, biopsy, or blood tests (like AFP).
- You have a history of chronic hepatitis B or C infection.
- You have fatty liver disease (MASLD) confirmed by a scan (FibroScan or ultrasound) and at least one metabolic risk factor such as obesity, type 2 diabetes, or high blood pressure.
- You do not have other causes of liver disease like autoimmune hepatitis, hemochromatosis, or Wilson's disease.
- You do not have any other type of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether continuing antiviral therapy after surgery for hepatitis B-related liver cancer can improve outcomes. It focuses on patients with early-stage disease, good liver function, and no prior cancer treatments other than surgery or ablation.
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
This study reviews medical records of people diagnosed with hepatocellular carcinoma (liver cancer) between 2015 and 2023 to better understand how the disease progresses and how different treatments work. Your information helps researchers learn what care approaches work best for future patients.
This study looks at your risk of developing liver cancer (hepatocellular carcinoma) if you have a liver condition such as NAFLD or a related disease. It aims to improve how doctors predict who might be at higher risk, so they can offer better monitoring and care.
This study examines blood and tissue samples from people with HIV, people without HIV, and healthy volunteers to understand how fatty liver disease develops and progresses. Researchers hope to find new ways to detect and treat fatty liver disease, especially in people living with HIV.
This trial is testing a routine screening program for liver cancer (hepatocellular carcinoma) in people who are at higher risk of developing it. The goal is to catch cancer early, when treatment works best.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.